RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00035024.xml
PDF herunterladen
Thromb Haemost 2004; 92(01): 208-210
DOI: 10.1055/s-0037-1613642
DOI: 10.1055/s-0037-1613642
Case Report
Intraoperative management of a congenital antithrombin deficient patient on chronic hemodialysis
Authors
Weitere Informationen
Publikationsverlauf
Received
29. November 2003
Accepted after revision
02. April 2004
Publikationsdatum:
15. Dezember 2017 (online)
-
References
- 1 Matsuo T, Yamada T, Yamanashi T. et al. Choice of anticoagulant in a congenital antithrombin III (AT III) deficient patient with chronic renal failure undergoing regular haemodialysis. Clin Lab Haematol 1989; 11 (03) 213-9.
- 2 Ota K, Akizawa T, Hirasawa Y. et al. Effect of argatroban as an anticoagulant for haemodialysis in patients in patients with antithrombin III deficiency. Nephrol Dial Transplant 2003; 18: 1623-30.
- 3 Beresford CH. Antithrombin III deficiency. Blood Rev 1988; 02 (04) 239-50.
- 4 O’Shea SI, Ortel TL, Kovalik EC. Alternative Methods of Anticoagulation for Dialysis-dependent Patients with Heparin-induced Thrombocytopenia. Semin Dial 2003; 16 (01) 61-7.
- 5 Swan SK, St Peter JV, Lambrecht LJ. et al. Comparison of anticoagulant effects and safety of argatroban and heparin in healthy subjects. Pharmacotherapy 2000; 20 (07) 756-70.
- 6 Tengborn L, Bergqvist D. Surgery in patients with congenital antithrombin III deficiency. Acta Chir Scand 1988; 154 (03) 179-83.
- 7 Lewis BE, Wallis DE, Berkowitz SD. et al. argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 2001; 103 (14) 1838-43.
- 8 Kathiresan S, Shiomura J, Jang IK. Argatroban. J Thromb Thrombolysis 2002; 13 (01) 41-7.
- 9 Swan SK, Hursting MJ. The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy 2000; 20 (03) 318-29.
- 10 Sundaram S, Gikakis N, Hack CE. et al. Nafamostat mesilate, a broad spectrum protease inhibitor, modulates platelet, neutrophil and contact activation in simulated extracorporeal circulation. Thromb Haemost 1996; 75 (01) 76-82.